PEAR Therapeutics Completes $50 Million Series B Financing

PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that it has successfully closed a $50 million Series B financing led by Temasek.

Read Article

ARCHIVES

2024 (14)
- April (2)
- March (2)
- February (5)
- January (5)
2023 (35)
- December (1)
- November (3)
- October (3)
- September (5)
- August (1)
- July (2)
- June (2)
- May (5)
- April (4)
- March (3)
- February (2)
- January (4)
2022 (40)
- December (2)
- November (3)
- October (3)
- September (5)
- August (4)
- July (2)
- June (5)
- May (5)
- April (3)
- March (2)
- February (3)
- January (3)
2021 (72)
- December (5)
- November (3)
- October (10)
- September (8)
- August (9)
- July (3)
- June (6)
- May (6)
- April (1)
- March (9)
- February (4)
- January (8)
2020 (49)
- December (3)
- November (3)
- October (3)
- September (6)
- August (3)
- July (5)
- June (5)
- May (6)
- April (1)
- March (5)
- February (2)
- January (7)
2019 (44)
- December (3)
- November (2)
- October (4)
- September (4)
- August (2)
- July (5)
- June (7)
- May (3)
- April (4)
- March (2)
- February (2)
- January (6)
2018 (49)
- December (3)
- November (6)
- October (3)
- September (3)
- August (5)
- July (2)
- June (1)
- May (6)
- April (6)
- March (7)
- February (2)
- January (5)

Previous PostSI-BONE, Inc. Announces Blue Cross Blue Shield Association Raises Clinical Evidence Rating for MIS SI Joint Fusion
Next PostAfter grim diagnosis, former Entergy CEO gives $1 million to Ochsner clinical trial initiative for cancer patients

PEAR Therapeutics Completes $50 Million Series B Financing

News & Insights

ARCHIVES

Previous PostSI-BONE, Inc. Announces Blue Cross Blue Shield Association Raises Clinical Evidence Rating for MIS SI Joint Fusion

Next PostAfter grim diagnosis, former Entergy CEO gives $1 million to Ochsner clinical trial initiative for cancer patients